Crown Laboratories and its affiliate Reba Merger Sub will now pay for the shares, which will cost the company $314.6 million.

Crown Labs, which agreed to acquire Revance Therapeutics for $6.66 a share in cash last month, was expected to start a tender offer by a Friday deadline, according to an 8-K filing from Aug. 28.

Over 10 years, the company raised $544 million from investors like Saudi Crown Prince Mohammed bin Salman, Mercedes-Benz and Intel. However, the company struggled to secure the additional funding ...

Thiruvananthapuram: Congress MP Shashi Tharoor on Saturday said that Kerala's startup ecosystem has become a "glittering jewel in the crown of India's fast-growing startup landscape" by ...